about
Male germ cell-associated kinase is overexpressed in prostate cancer cells and causes mitotic defects via deregulation of APC/CCDH1Phosphorylation of ETS1 by Src family kinases prevents its recognition by the COP1 tumor suppressorPrevalence of TMPRSS2-ERG and SLC45A3-ERG gene fusions in a large prostatectomy cohortMay the Best Molecule Win: Competition ESI Mass SpectrometryHypothesis: Artifacts, Including Spurious Chimeric RNAs with a Short Homologous Sequence, Caused by Consecutive Reverse Transcriptions and Endogenous Random PrimersTargeting prostate cancer stem cells for cancer therapyDiscovery and Classification of Fusion Transcripts in Prostate Cancer and Normal Prostate TissueEpigenomic profiling of prostate cancer identifies differentially methylated genes in TMPRSS2:ERG fusion-positive versus fusion-negative tumors.Cancer biomarker discovery: the entropic hallmark.Getting personal with prostate cancer: adding new pieces to an incomplete jigsaw puzzle.A DNA methylation microarray-based study identifies ERG as a gene commonly methylated in prostate cancerChromosomal minimal critical regions in therapy-related leukemia appear different from those of de novo leukemia by high-resolution aCGH.Influence of oncogenic transcription factors on chromatin conformation and implications in prostate cancer.Zbtb7a suppresses prostate cancer through repression of a Sox9-dependent pathway for cellular senescence bypass and tumor invasion.Molecular characterisation of ERG, ETV1 and PTEN gene loci identifies patients at low and high risk of death from prostate cancer.Family with sequence similarity 13C (FAM13C) overexpression is an independent prognostic marker in prostate cancer.Cysteine-rich secretory protein-3 (CRISP3) is strongly up-regulated in prostate carcinomas with the TMPRSS2-ERG fusion geneMechanistic heterogeneity in site recognition by the structurally homologous DNA-binding domains of the ETS family transcription factors Ets-1 and PU.1.Chemopreventive mechanisms of α-keto acid metabolites of naturally occurring organoselenium compounds.Characterization of genetic rearrangements in esophageal squamous carcinoma cell lines by a combination of M-FISH and array-CGH: further confirmation of some split genomic regions in primary tumors.Inactivation of ATM/ATR DNA damage checkpoint promotes androgen induced chromosomal instability in prostate epithelial cellsHistone modifications and chromatin organization in prostate cancer5' UTR control of native ERG and of Tmprss2:ERG variants activity in prostate cancerERG induces epigenetic activation of Tudor domain-containing protein 1 (TDRD1) in ERG rearrangement-positive prostate cancer.A three-marker FISH panel detects more genetic aberrations of AR, PTEN and TMPRSS2/ERG in castration-resistant or metastatic prostate cancers than in primary prostate tumors.TMPRSS2-ERG-mediated feed-forward regulation of wild-type ERG in human prostate cancers.TMPRSS2-ERG status in circulating tumor cells as a predictive biomarker of sensitivity in castration-resistant prostate cancer patients treated with abiraterone acetate.The oncogenic gene fusion TMPRSS2: ERG is not a diagnostic or prognostic marker for ovarian cancer.Reconstitution of the ERG Gene Expression Network Reveals New Biomarkers and Therapeutic Targets in ERG Positive Prostate TumorsOncogenic activation of ERG: A predominant mechanism in prostate cancer.Hormones and prostate carcinogenesis: Androgens and estrogens.High-Level HOOK3 Expression Is an Independent Predictor of Poor Prognosis Associated with Genomic Instability in Prostate CancerRelative mRNA expression of prostate-derived E-twenty-six factor and E-twenty-six variant 4 transcription factors, and of uridine phosphorylase-1 and thymidine phosphorylase enzymes, in benign and malignant prostatic tissue.Outsmarting androgen receptor: creative approaches for targeting aberrant androgen signaling in advanced prostate cancerOncogenic activation in prostate cancer progression and metastasis: Molecular insights and future challenges.Effects of oxygen on the antigenic landscape of prostate cancer cells.ETV1, 4 and 5: an oncogenic subfamily of ETS transcription factors.SLFN11 Is a Transcriptional Target of EWS-FLI1 and a Determinant of Drug Response in Ewing Sarcoma.Molecular diagnostic trends in urological cancer: biomarkers for non-invasive diagnosis.Landscape of gene fusions in epithelial cancers: seq and ye shall find.
P2860
Q24292955-59AC38B4-9B6B-4606-A046-7D9B013D0BC5Q24301920-58DC81EC-888E-48B4-8465-CBDDDAF10E8BQ24606772-F13761FB-391D-4F50-9827-5EAAE3277963Q26779012-776B4744-6998-4A82-AB99-A973FE0BFE3BQ26820767-D8AD5243-21CB-4E66-92DF-36D061BDB896Q26865693-33E324E1-F4D5-4CE5-924C-34D799D721D9Q26997884-9A8F04FA-4EFA-49D4-A2D1-87CF017763BCQ27323950-15BB47B6-5C51-45A5-9210-047F5B7F10C3Q30496149-1C57E8BA-AD6B-4AF5-8194-3B005550F139Q33351113-EACD7E92-50E9-431A-872E-27AA7C4CAA2BQ33390454-8641ACA3-0D7A-4B44-A10F-D8F0F7B37267Q33394269-824A6CFD-C228-416A-A2D0-4DB8E97348FCQ33675577-E01C8661-7F4E-4DF6-8A64-9B8EB3091590Q33677421-E3AC68A0-619C-41B3-A2CE-5113CCD05FDCQ33723651-362A5443-D78B-4F63-B9C8-19836875D5BFQ33761801-72E1FE7D-395B-4668-AC5F-9144EC79C7FFQ33981506-956BA366-B211-46EA-882E-C163CCBEA634Q33985362-1685FC0D-3ADE-46E3-9801-957913F5E165Q34249695-7AD8C927-59D1-45A9-A741-CBFDD00570FFQ34392987-BF8A8E39-D357-4231-B52D-42A95BF293F8Q34525129-6C41C8ED-29B1-4CD1-94AA-FCBE59CE6DAAQ34559303-99673F11-7E62-4390-B8B2-1971104A2DACQ34614232-8A9799C0-C043-4571-9CFF-EC8CD916FA1DQ34652823-576DA5EA-B623-408E-8D75-E90F2A7FCCECQ35009891-0D88F7C4-06C5-4AAF-B809-8C56637819B1Q35165354-1301C0C6-B596-4F21-9AAB-FA304384D470Q35256427-C48E6C5B-B05B-4628-A3BD-7D244252163BQ35532282-A9584026-2E80-42DD-A4B9-D66F1BAE7F4EQ35631603-4AC04D2C-ACCB-4A54-BAA6-F95A5F249069Q35685920-AA112A99-E2EA-43E7-A3CF-370B0E2A171CQ35687198-412CB762-AEF4-4222-9CC4-70E7466ECC6BQ35731092-F0BCC5AC-1DDB-47F1-8DC2-139A3B2DE3E4Q35758944-014792E4-2FB4-47CF-B607-71BFCE8D6997Q35786826-05950493-0AA2-4858-9967-E5FF27BE15D4Q35838821-DB17CB30-CF92-46B6-893C-761F58AEE7FCQ35845496-172240D1-A9FE-4C8E-8622-0EDE383E7089Q35996105-FA442CCA-7975-4E88-85D4-4360081FC1B7Q36069053-016CC2EE-74AA-4022-8AED-B518DDDAE7E3Q36190604-78AC5611-EFDC-4C6A-A64B-05ED9DB4F4EBQ36383369-2D5D027E-EBBD-40C1-A54F-0D94462BECE3
P2860
description
article científic
@ca
article scientifique
@fr
articolo scientifico
@it
artigo científico
@pt
bilimsel makale
@tr
scientific article published on August 2009
@en
vedecký článok
@sk
vetenskaplig artikel
@sv
videnskabelig artikel
@da
vědecký článek
@cs
name
ETS gene fusions in prostate cancer.
@en
ETS gene fusions in prostate cancer.
@nl
type
label
ETS gene fusions in prostate cancer.
@en
ETS gene fusions in prostate cancer.
@nl
prefLabel
ETS gene fusions in prostate cancer.
@en
ETS gene fusions in prostate cancer.
@nl
P356
P1476
ETS gene fusions in prostate cancer.
@en
P2093
Colin S Cooper
Jeremy P Clark
P2888
P304
P356
10.1038/NRUROL.2009.127
P407
P577
2009-08-01T00:00:00Z
P6179
1030944708